Synthesis and serotonergic activity of 3-[2-(pyrrolidin-1- yl)ethyl]indoles: Potent agonists for the h5-HT(1D) receptor with high selectivity over the h5-HT(1B) receptor

Journal of Medicinal Chemistry

Volumn 42, Issue 4, 1999, Pages 677-690

  Sternfeld, Francine ^a   Guiblin, Alexander R ^a   Jelley, Richard A ^a   Matassa, Victor G ^a   Reeve, Austin J ^a   Hunt, Peter A ^a   Beer, Margaret S ^a   Heald, Anne ^a   Stanton, Josephine A ^a   Sohal, Bindi ^a   Watt, Alan P ^a   Street, Leslie J ^a  

^a NEUROSCIENCE RESEARCH CENTRE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

3 [2 (PYRROLIDIN 1 YL)ETHYL]INDOLE DERIVATIVE; ANTIMIGRAINE AGENT; ELETRIPTAN; NARATRIPTAN; RIZATRIPTAN; SEROTONIN 1B RECEPTOR; SEROTONIN 1D AGONIST; SUMATRIPTAN; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CHO CELL; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; MIGRAINE; NONHUMAN; RAT; STRUCTURE ANALYSIS;

EID: 0033602128     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm9805687     Document Type: Article

References (45)

1. Plosker, G. L.; McTavish, D. Sumatriptan: A Reappraisal of its Pharmacology and Therapeutic Efficacy in the Acute Treatment of Migraine and Cluster Headache. Drugs 1994, 47, 622-651.
2. Hoyer, D.; Bell, G. I.; Berelowitz, M.; Epelbaum, J.; Feniuk, W.; Humphrey, P. P. A.; O'Carroll, A. M.; Patel, Y. C.; Schonbrunn, A. Classification and Nomenclature of Serotonin Receptors. Trends Pharmacol. Sci. 1995, 16, 86-8.
3. 1Dβ Receptors. Eur. J. Pharmacol. 1995, 287, 79-84.
4. Hoyer, D.; Martin, G. 5-HT Receptor Classification and Nomenclature: Towards a Harmonisation With the Human Genome. Neuropharmacology 1997, 36, 419-428.
5. 1D Receptors: Pharmacology and Therapeutic Potential. Serotonin 1996, 1, 19-29.
6. Ottervanger, J. P.; van Witsen, T. B.; Valkenburg, H. A.; Grobbee, D. E.; Stricker, B. H. Adverse Reactions Attributed to Sumatriptan. A Postmarketing Study in General Practise. Eur. J. Clin. Pharmacol. 1994, 47, 305-309.
7. (a) Bax, W. A.; Rezenbrink, G. J.; van Heuven-Nolsen, D.; Thijssen, E. J. M.; Bos, E.; Saxena, P. R. 5-HT Receptors Mediating Contractions of Isolated Human Coronary Artery. Eur. J. Pharmacol. 1993, 239, 203-210.
8. 1Dβ receptors. Circulation 1994, 90, 1141-1153.
9. Rizatriptan has been shown to have a lower propensity than Sumatriptan in causing contraction of isolated human artery segments: (a) Ferro, A.; Longmore, J.; Hill, R. G.; Brown, M. J. A. Comparison of the Contractile Effects of 5-Hydroxytryptamine, Sumatriptan and MK-462 on Human Coronary Artery in vitro. Br. J. Clin. Pharmacol. 1995, 40 (3), 245-251.
10. 1D Receptor Agonists and Human Coronary Artery Reactivity in vitro: Crossover Comparisons of 5-HT and Sumatriptan with Rizatriptan and L-741,519. Br. J. Clin. Pharmacol. 1996, 42, 431-441.
11. Humphrey, P. P. A.; Goadsby, P. J. The Mode of Action of Sumatriptan is Vascular? A Debate. Cephalagia 1994, 14, 401-410.
12. Buzzi, M. G.; Bonamini, M.; Moskowitz, M. A. Neurogenic Model of Migraine. Cephalagia 1995, 15, 277-280.
13. 1D Agonist Drugs: Selectively Targeting Additional Sites of Action. Eur. Neurol. 1996, 36, 13-18.
14. Bouchelet, I.; Cohen, Z.; Case, B.; Seguela, P.; Hamel, E. Differential Expression of Sumatriptan-Sensitive 5-Hydroxytryptamine Receptors in Human Trigeminal Ganglia and Cerebral Blood Vessels. Mol. Pharmacol. 1996, 50, 219-223.
15. 1B Subtype. J. Med. Chem. 1997, 40, 3497-3500.
16. 1D) Receptors. Bioorg. Med. Chem. Lett. 1996, 6, 1825-1830.
17. Although small, the difference in selectivity between 3b and 4 (9-fold vs 4.3-fold) is statistically significant. Further support for the inherent selectivity of the pyrrolidine base versus tryptamine is provided by the observation that the N-methyl-N-benzyl analogue of 4 is only marginally selective (4-fold).
18. 1Dβ Receptors. Eur. J. Med. Chem. 1997, 32, 59-69.
19. Nielsen, L.; Brehm, L.; Krogsgaard-Larsen, P. GABA Agonists and Uptake Inhibitors. Synthesis, Absolute Stereochemistry and Enantioselectivity of (R)-(-)-and (S)-(+)-Homo-β-proline. J. Med. Chem. 1990, 33, 71-77.
20. Fleming, I.; Pearce, A. Controlling the Outcome of a Carbocation-Initiated Cylisation. J. Chem. Soc., Perkin Trans. 1 1981, 251-255.
21. 1D Receptor Agonist MK-462 via a Pd-Catalysed Coupling Reaction. Tetrahedron Lett. 1994, 35, 6981-6984.
22. Note that, in the case of 12a, this operation results in inversion of the pyrrolidine C-3 chiral center.
23. Synthesis of the methylene-bridged triazol-lyltryptophol required for the preparation of 22a-d is described in ref 19.
24. (a) Macor, J. E.; Blank, D. H.; Post, R. J.; Ryan, K. Synthesis of a Conformationally Restricted Analogue of the Anti-Migraine Drug Sumatriptan. Tetrahedron Lett. 1992, 33, 8011-14.
25. 1D Receptor: Discovery of Compounds with Potential Anti-Migraine Properties. J. Med. Chem. 1995, 38, 3566-3580.
26. (c) Robertson, A. D.; Hill, A. P.; Glen, R. C.; Martin, G. R. Therapeutic Heterocyclic Compounds. World Patent Appl. WO 91/18897.
27. 1 Receptor Agonists. World Patent Appl. WO 96/17842, 1996.
28. (b) Bishop, B. C.; Cottrell, I. F.; Hands, D. Synthesis of 3-Hydroxyalkylbenzo[b]furans via the Palladium-Catalysed Heteroannulation of Silyl-Protected Alkynols with 2-Iodophenol. Synthesis 1997, 1315-1320.
29. 1D Receptor Subtype. Mol. Pharmacol. 1992, 42, 439-444.
30. 35S]GTPγS is resistant to this GTPase, it accumalates in the membrane and can be measured by virtue of its radiolabel. See, for example, ref 26.
31. 35S]GTPγS Binding Mediated by Human Muscarinic m1-m4 Receptors: Antagonist Studies. Br. J. Pharmacol. 1993, 109, 1120-1127.
32. Inflammation of the dura in animals, induced by electrical stimulation of the trigeminal ganglion, has been proposed as a possible model of migraine. See ref 10.
33. 50 130 nM; maximal efficacy 101% relative to 5-HT).
34. 1D Receptor Agonists as Potential Antimigraine Agents. J. Med. Chem. 1997, 40, 3501-3503.
35. 1D receptor agonists See ref 13.
36. The structures are local low-energy conformers found using the SYBYL minimization routine with the TRIPOS force field and Gasteiger-Huckel charges on the protonated species. The overlays were formed by directly overlaying the indole rings.
37. Hunt, P. A.; McAllister, G.; Sinclair, H. Unpublished results.
38. 40 based upon the bacteriorhodopsin template as a starting point. Modifications to this starting conformation were made using the SYBYL modeling software from TRIPOS to produce a sensible, energetically favorable structure which conformed to our in-house results. These modifications included helix rotations and translations as well as the introduction of the loop regions between each helix including dynamics and energy minimizations (TRIPOS force field, Gasteiger-Huckel charges with neutral amino acids) with and without agonists bound.
39. 1B 910 nM.
40. 1F 27 nM.
41. Further evidence for the contribution of the N-4-linked triazole to poor oral absorption is provided by comparison of the hepatic portal vein concentrations of 3b (135 and 31 ng/mL at 0.5 and 2 h postdose) with those of {2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethyl}pyrrolidine (254 and 263 ng/mL at 0.5 and 2 h pastdose).
42. Bartlett, R. K.; Humphrey, I. R. Transaminations of N,N-Dimethylformamide Azine. J. Chem. Soc. C 1967, 1664-1666.
43. Hughes, L. R.; Oldfield, J.; Pegg, S. J.; Barker, A. J.; Marsham, P. R. Anti-tumour Agents. EP 0373 891 A2.
44. Ciganek, E. Tertiary Carbinamines by Addition of Organocerium Reagents to Nitriles and Ketimines. J. Org. Chem. 1992, 57, 4521-4527.
45. Horn, F.; Weare, J.; Beukers, M. W.; Horsch, S.; Bairoch, A.; Chen, W.; Edvardsen, O.; Campagne, F.; Vriend, G. GPCRDB: an information system for G protein coupled receptors. Nucleic Acids Res. 1988, 26, 277-281.